Fitness and virulence of a Coxsackievirus mutant that can circumnavigate the need for phosphatidylinositol 4-kinase class III beta by Thibaut, Hendrik Jan et al.
  Published Ahead of Print 26 December 2013. 
2014, 88(5):3048. DOI: 10.1128/JVI.03177-13. J. Virol. 
Johan Neyts and Frank J. M. van Kuppeveld
Lanke, Erik Verbeken, Martin Andrews, Pieter Leyssen, 
Hendrik Jan Thibaut, Hilde M. van der Schaar, Kjerstin H. W.
 
Beta
for Phosphatidylinositol 4-Kinase Class III
Mutant That Can Circumnavigate the Need 
Fitness and Virulence of a Coxsackievirus
http://jvi.asm.org/content/88/5/3048




This article cites 10 articles, 7 of which can be accessed free at:
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n














Fitness and Virulence of a Coxsackievirus Mutant That Can
Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III
Beta
Hendrik Jan Thibaut,a Hilde M. van der Schaar,a Kjerstin H. W. Lanke,b Erik Verbeken,c Martin Andrews,d Pieter Leyssen,e
Johan Neyts,e Frank J. M. van Kuppevelda
Department of Infectious Diseases & Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlandsa; Department of Medical
Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlandsb; Translational Cell & Tissue
Research, Department of Imaging & Pathology, University of Leuven, Leuven, Belgiumc; Galapagos NV, Mechelen, Belgiumd; Laboratory of Virology and Chemotherapy,
Rega Institute for Medical Research, University of Leuven, Leuven, Belgiume
Coxsackieviruses require phosphatidylinositol-4-kinase III (PI4KIII) for replication but can bypass this need by an H57Ymu-
tation in protein 3A (3A-H57Y). We show that mutant coxsackievirus is not outcompeted by wild-type virus during 10 passages
in vitro. In mice, the mutant virus proved as virulent as wild-type virus, even when mice were treated with a PI4KIII inhibitor.
Our data suggest that upon emergence, the 3A-H57Ymutant has the fitness to establish a resistant population with a virulence
similar to that of wild-type virus.
Enteroviruses, belonging to the family of the Picornaviridae, aresmall, positive-stranded RNA viruses and include many im-
portant human pathogens, including poliovirus, rhinovirus, cox-
sackievirus, and enterovirus 71. Since the genus Enterovirus
comprises more than 250 (sero)types, the development of a pan-
enterovirus vaccine will be unfeasible. Hence, the development of
broad-spectrum antienteroviral drugs will be crucial for disease
control. Like most RNA viruses, enteroviruses have a high muta-
tion rate, resulting in a rapid emergence of drug resistance which
eventually could lead to therapy failure. Drugs that target host
factors that are crucial for virus replication are believed to impede
this process. In recent years, several studies identified the essential
membrane-modifying host cell factor phosphatidylinositol-4-ki-
nase III (PI4KIII) as the target of broad-spectrum and highly
potent inhibitors of enterovirus replication (1–8). However, fol-
lowing lengthy selection processes, coxsackievirus B3 (CVB3)
mutants that are resistant to these inhibitors emerged and were
shown to harbor single point mutations in the nonstructural pro-
tein 3A (4, 7, 8). The H57Y mutation (3A-H57Y) was identified
most frequently and provided the strongest resistance against
PI4KIII inhibitors, as well as to depletion of this factor. This
indicates that the mutant coxsackievirus can bypass this host fac-
tor and/or the need for its product, phosphatidylinositol-4-phos-
phate (PI4P), in cell culture (8).
The aim of this study was to explore the fitness of this mutant
virus that can replicate independently of a host factor that is es-
sential for the replication of the wild-type (wt) virus.We therefore
studied whether the PI4KIII-independent CVB3 mutant would
be outgrown by wt virus within a mixed population. Previously,
we performed a side-by-side comparison of the replication kinet-
ics of both viruses in a single replication cycle in vitro. CVB3 3A-
H57Y was shown to grow with kinetics similar to those of the wt
virus in the absence of a PI4KIII inhibitor, suggesting that nei-
ther virus is able to outcompete the other (8). However, single-
replication-cycle assays do not allow the detection of slight differ-
ences in the growth kinetics between two virus populations.
Therefore, a multicycle growth-competition experiment was car-
ried out, in which BGM cells were infected at a multiplicity of
infection of 0.001 with either wt CVB3 (strain Nancy) or CVB3
3A-H57Y or were coinfected with amixture of the viruses at a ratio
of 1:1 or 1:10 (wt/mutant).When cytopathic effect became appar-
ent, the virus cultures were harvested by freeze-thawing and were
titrated for infectious virus content. This process was repeated for
10 consecutive passages, and the ratio of mutant to wt virus was
analyzed in every passage. To this end, viral RNA was isolated
(Qiagen), reverse transcription (RT)-PCR was carried out using
random hexamer primers (Roche), and the resulting cDNA (Fig.
1B and C, RT-PCR input) was then used as a template in a PCR.
This reaction was performed with primers designed around the
H57Y mutation (forward primer, 5=-TAA TAC GAC TCA CTA
TAG GAT AGC GTG GGG ACC ACG-3=, and reverse primer,
5=-ATT AAC CTC CAC TTC CTC CTT GGC-3=) to yield a 622-
nucleotide (nt) DNA product. Next, a genotype-specific digestion
was performed using restriction enzyme NspI, which only
cleaves cDNA amplified from the wt CVB3, resulting in two
fragments of 435 nt and 187 nt (Fig. 1A). Consequently, RNA
isolated from CVB3 3A-H57Y is represented by a single 622-nt
product (Fig. 1A).
When wt virus was mixed with an equal amount of CVB3 3A-
H57Y, products fromboth viruses could be readily detected during
10 consecutive passages. We observed that after 3 passages, the
viral RNA ratio shifted from favoring CVB3 3A-H57Y toward
favoring wt CVB3 (Fig. 1B and C). However, it remains unclear
why this shift occurred. Nevertheless, CVB3 3A-H57Y was not
outcompeted by the wt virus throughout the course of the exper-
iment. This finding was further substantiated by using a 10-fold
excess of mutant over wt CVB3 (1:10 ratio, wt to mutant), which
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revealed the sole presence of the CVB3 3A-H57Y product. Alto-
gether, these observations suggest that upon emergence, CVB3
3A-H57Y may have the fitness to establish a resistant virus popu-
lation, at least in vitro.
A comparable fitness of two virus variants in vitro does not
necessarily imply a comparable virulence in the infected host. Im-
portantly, these growth competition experiments were performed
in the absence of a PI4KIII inhibitor. Since we previously dem-
onstrated that the presence of such inhibitor induced a 1- to 2-h
delay in a single replication cycle of the mutant virus in vitro, we
wondered whether this delay in vitro might be translated to an
impaired virulence in vivo (8). To this end, we studied the repli-
cation of both viruses in a CVB-induced pancreatitis mouse
model that has been described previously (9). In thismodel, virus-
induced pancreatic tissue damage is the most prominent symp-
tom and, hence, it served as the basis to study viral fitness. Em-
ploying this model, we compared the virulence and pathogenicity
of wt CVB3 and CVB3 3A-H57Y, either in the absence or presence
of compound 2 (a recently published PI4KIII inhibitor of en-
terovirus replication both in vitro and in vivo [7]).Mice (n 5 per
group) were infected intraperitoneally with equivalent amounts
(5 105 TCID50/ml) of either wt virus or CVB3 3A-H57Y, which
was previously determined to result in a peak of pancreatic symp-
toms at day 3 postinfection (data not shown). Immediately after
infection, mice were treated (via the subcutaneous route) twice
daily with 50 mg/kg of body weight/day of compound 2 or were
left untreated (Fig. 2). At 3 days postinfection, the mice were sac-
rificed, and following extensive transcardial perfusion with phos-
phate-buffered saline, the pancreas was removed. One part of the
pancreas was fixed in 4% formaldehyde and embedded in paraf-
FIG 1 (A) Schematic representation of the basis of RT-PCR for analysis of a coinfection growth-competition experiment between wt and 3A-H57Y CVB3. BGM
cells were infected either withwt ormutant CVB3 orwith amixture of both viruses (ratios of 1:1 and 1:10) for 10 consecutive passages. Viral RNAswere extracted
after every passage, and RT-PCR products were digested with NspI and visualized on a 1% agarose gel using ethidium bromide. Cleavage products are indicated
with lines. (B) Gels for passages 1 to 4 (P1 to P4). (C) Gels for passages 6, 8, and 10. (Top) Input cDNA for restriction analysis following RT-PCR.
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fin. Tissue sections were stained with hematoxylin and eosin, and
histopathological damage was quantified using a standardized
scoring system ranging from 0 (absence of damage) to 3 (diffuse
damage throughout the tissue) (10). Histopathological analysis
revealed similar scores for interstitial inflammation, necrosis, and
edema in mice infected with either wt virus or 3A-H57Y CVB3.
Compound2provided complete protection against all parameters
of pancreatitis in mice infected with wt CVB3, whereas no protec-
tive effects were observed in mice infected with CVB3 3A-H57Y
(Fig. 2A). Interestingly, the signs of inflammation in these mice
were comparable to those of untreated infectedmice, suggesting a
similar virulence even in the presence of the compound.
Another part of the pancreas was homogenized in saline using
mechanical disruption (Precellys 24; Bertin) to quantify infectious
virus titers by means of endpoint titrations, expressed as the 50%
cell culture infectious dose (TCID50) perml (Fig. 2B). As amarker
for pancreatitis, we also quantified the serum amylase and lipase
levels, using an enzymatic colorimetric reaction (Cobas/Roche)
on the modular P analyzer (Roche Diagnostics). To this end, 500
l of blood was collected by cardiac puncture before the transcar-
dial perfusion, and following 1 h of incubation at room tempera-
ture, blood was centrifuged at 13,000 rpm for 10 min (Fig. 2C).
Similar to the histopathological analysis, the virus titers and
amylase/lipase levels of untreated infected animals did not differ
FIG 2 Effects of compound 2 in CVB3-induced pancreatitis. Mice were infected with wt or 3A-H57Y CVB3 and treated subcutaneously twice a day with 50
mg/kg/day of compound 2 or were left untreated. Effects on histopathology scores (A), virus replication (B), and biochemical parameters for pancreatitis (C) are
shown. Data are presented as means standard deviations (n 5). Statistical significance was calculated by means of the Mann-Whitney U test.
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significantly from those of the treated, CVB3 3A-H57Y-infected
animals. On the contrary, mice treated with compound 2 and
infectedwithwtCVB3 exhibited amarked reduction of virus titers
(4 log10) and normalization of amylase and lipase levels.
Overall, our data demonstrate that, upon acquiring an H57Y
mutation in protein 3A, CVB3 exhibited a reduced drug suscepti-
bility to PI4KIII inhibitors not only in vitro but also in the in-
fected host. Although our previous in vitro studies suggested a
reduced fitness of this mutant CVB3 in the presence of a PI4KIII
inhibitor, this was not translated to an impaired virulence or
pathogenicity in vivo (either in in the absence or presence of such
an inhibitor). Furthermore, we show that in a 1:1 mixture with wt
virus, CVB3 3A-H57Y was not outcompeted by wt virus but re-
mained present in the viral population throughout the course of
the experiment. Collectively, these data suggest that upon the
emergence of CVB3 3A-H57Y in vivo under the selective pressure
of a PI4KIII inhibitor, this mutant virus has sufficient fitness to
compete with wt virus and to establish a resistant virus population
with a similar virulence.However, given the lengthy selection pro-
cess in vitro and the fact that, thus far, only one 3A-H57Y isolate
has been recovered from a patient (GenBank accession number
JQ040513), it remains questionable whether this mutation would
emerge during a short-acting treatment of these acute infections
in infected patients.
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